{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:11:19Z","timestamp":1790907079493,"version":"4.1.0"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1097\/01.aog.0000295638.83285.97","type":"journal-article","created":{"date-parts":[[2010,11,30]],"date-time":"2010-11-30T07:38:54Z","timestamp":1291102734000},"page":"1404-1416","source":"Crossref","is-referenced-by-count":20,"title":["Screening and Follow-up of the Patient at High Risk for Breast Cancer"],"prefix":"10.1097","volume":"110","author":[{"given":"Shawna C.","family":"Willey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costanza","family":"Cocilovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-31-20210201","first-page":"26","article-title":"Breast cancer: a practical guide. 3rd ed.","author":"Silva","year":"2005"},{"key":"R3-31-20210201","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1093\/jnci\/81.24.1879","article-title":"Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.","volume":"81","author":"Gail","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"R5-31-20210201","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/jnci\/93.5.334","article-title":"Validating and improving models for projecting the absolute risk of breast cancer.","volume":"93","author":"Gail","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"R6-31-20210201","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5","article-title":"Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction.","volume":"73","author":"Claus","year":"1994","journal-title":"Cancer"},{"key":"R8-31-20210201","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/oxfordjournals.epirev.a036102","article-title":"Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk.","volume":"15","author":"Pike","year":"1993","journal-title":"Epidemiol Rev"},{"key":"R9-31-20210201","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1001\/jama.283.4.485","article-title":"Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk [published erratum appears in JAMA 2000;284:2597].","volume":"283","author":"Schairer","year":"2000","journal-title":"JAMA"},{"key":"R10-31-20210201","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJM198501173120303","article-title":"Risk factors for breast cancer in women with proliferative breast disease.","volume":"312","author":"Dupont","year":"1985","journal-title":"N Engl J Med"},{"key":"R11-31-20210201","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1002\/1097-0142(19930215)71:4<1258::AID-CNCR2820710415>3.0.CO;2-I","article-title":"Breast cancer risk associated with proliferative breast disease and atypical hyperplasia.","volume":"71","author":"Dupont","year":"1993","journal-title":"Cancer"},{"key":"R12-31-20210201","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0360-3016(03)01460-3","article-title":"Fifteen-year results of breast-conserving surgery and definitive irradiation for Stage I and II breast carcinoma: the University of Pennsylvania experience.","volume":"58","author":"Santiago","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R13-31-20210201","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1053\/ctrv.2000.0174","article-title":"Breast cancer risk following irradiation for Hodgkin's disease.","volume":"26","author":"Clemons","year":"2000","journal-title":"Cancer Treat Rev"},{"key":"R14-31-20210201","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1667\/RR3082","article-title":"Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1990.","volume":"160","author":"Land","year":"2003","journal-title":"Radiat Res"},{"key":"R15-31-20210201","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jama.279.7.535","article-title":"Alcohol and breast cancer in women: a pooled analysis of cohort studies.","volume":"279","author":"Smith-Warner","year":"1998","journal-title":"JAMA"},{"issue":"suppl","key":"R16-31-20210201","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1002\/cncr.22654","article-title":"Diet and breast cancer: a review of the prospective observational studies.","volume":"109","author":"Michels","year":"2007","journal-title":"Cancer"},{"key":"R17-31-20210201","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/jnci\/91.6.529","article-title":"Meta-analysis: dietary fat intake, serum estrogen levels, and the risk of breast cancer.","volume":"91","author":"Wu","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"R18-31-20210201","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1093\/jnci\/dji372","article-title":"Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.","volume":"97","author":"Fisher","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"R20-31-20210201","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies [published erratum appears in Am J Hum Genet 2003;73:709].","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am J Hum Genet"},{"key":"R21-31-20210201","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1146\/annurev.med.53.082901.103925","article-title":"Breast cancer risk reduction: strategies for women at increased risk.","volume":"53","author":"Chlebowski","year":"2002","journal-title":"Annu Rev Med"},{"key":"R22-31-20210201","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/oxfordjournals.aje.a116266","article-title":"Breast cancer incidence in women with abnormal cytology in nipple aspirates of breast fluid.","volume":"135","author":"Wrensch","year":"1992","journal-title":"Am J Epidemiol"},{"key":"R23-31-20210201","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1677\/erc.1.01000","article-title":"Breast-tissue sampling for risk assessment and prevention.","volume":"12","author":"Fabian","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"R24-31-20210201","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/jnci\/95.13.971","article-title":"Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease.","volume":"95","author":"van Leeuwen","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"R25-31-20210201","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"R26-31-20210201","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"R27-31-20210201","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1097\/01.AOG.0000241091.86268.6e","article-title":"Breast cancer risk in postmenopausal women using estrogen-only therapy.","volume":"108","author":"Lyytinen","year":"2006","journal-title":"Obstet Gynecol"},{"key":"R28-31-20210201","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/annonc\/mdj127","article-title":"Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors.","volume":"17","author":"Kendall","year":"2006","journal-title":"Ann Oncol"},{"key":"R29-31-20210201","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/jnci\/87.21.1622","article-title":"Mammographic features and breast cancer risk: effects with time, age, and menopause status.","volume":"87","author":"Byrne","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"R30-31-20210201","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/jnci\/djm062","article-title":"Endogenous hormone levels, mammographic density, and subsequent risk of breast cancer in postmenopausal women.","volume":"99","author":"Tamimi","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"R31-31-20210201","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/S0140-6736(00)03258-X","article-title":"Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.","volume":"356","author":"Narod","year":"2000","journal-title":"Lancet"},{"key":"R32-31-20210201","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","article-title":"Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial.","volume":"286","author":"King","year":"2001","journal-title":"JAMA"},{"key":"R33-31-20210201","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1006478317173","article-title":"Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.","volume":"65","author":"Cauley","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"R34-31-20210201","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/jnci\/djh345","article-title":"Defining the role of raloxifene for the prevention of breast cancer.","volume":"96","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"R36-31-20210201","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1677\/erc.1.01227","article-title":"Novel concepts for the chemoprevention of breast cancer through aromatase inhibition.","volume":"13","author":"Kendall","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"R37-31-20210201","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199901143400201","article-title":"Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.","volume":"340","author":"Hartmann","year":"1999","journal-title":"N Engl J Med"},{"key":"R38-31-20210201","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/jnci\/93.21.1633","article-title":"Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.","volume":"93","author":"Hartmann","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"suppl","key":"R39-31-20210201","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","article-title":"Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.","volume":"346","author":"Rebbeck","year":"2002","journal-title":"N Engl J Med"},{"key":"R41-31-20210201","first-page":"821","article-title":"ACOG practice bulletin. Clinical management guidelines for obstetrician\u2013gynecologists. Number 42, April 2003. Breast cancer screening.","volume":"101","year":"2003","journal-title":"Obstet Gynecol"},{"key":"R42-31-20210201","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1001\/jama.292.22.2735","article-title":"Magnetic resonance imaging of the breast prior to biopsy.","volume":"292","author":"Bluemke","year":"2004","journal-title":"JAMA"},{"key":"R43-31-20210201","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1001\/jama.295.20.2374","article-title":"Cost-effectiveness of screening BRCA1\/2 mutation carriers with breast magnetic resonance imaging.","volume":"295","author":"Plevritis","year":"2006","journal-title":"JAMA"},{"key":"R44-31-20210201","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1245\/s10434-006-9195-5","article-title":"Results of MRI screening for breast cancer in high-risk patients with LCIS and atypical hyperplasia.","volume":"14","author":"Port","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"R45-31-20210201","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3322\/canjclin.57.2.75","article-title":"American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography [published erratum appears in CA Cancer J Clin 2007;57:185].","volume":"57","author":"Saslow","year":"2007","journal-title":"CA Cancer J Clin"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006250-200712000-00031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:45:48Z","timestamp":1786041948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006250-200712000-00031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/01.aog.0000295638.83285.97","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}